Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dapsone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 4/20 | 0.89 |
| ▸ | TSHR | P16473 | 3/20 | 0.89 |
| ▸ | LMNA | P02545 | 2/20 | 0.89 |
| ▸ | MPO | P05164 | 1/20 | 0.89 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.89 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.89 |
| ▸ | MEN1 | O00255 | 1/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | PKM | P14618 | 2/20 | 0.64 |
| ▸ | NT5E | P21589 | 1/20 | 0.64 |
| ▸ | CA1 | P00915 | 3/20 | 0.59 |
| ▸ | CA2 | P00918 | 3/20 | 0.59 |
| ▸ | CA12 | O43570 | 2/20 | 0.59 |
| ▸ | CA9 | Q16790 | 2/20 | 0.59 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.59 |
| ▸ | AGO2 | Q9UKV8 | 2/20 | 0.59 |
| ▸ | USP2 | O75604 | 1/20 | 0.59 |
| ▸ | CA4 | P22748 | 1/20 | 0.59 |
| ▸ | CA6 | P23280 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dapsone SCHEMBL21428 | 0.94 | HTR6 (1.00) | HTR6TSHRLMNAMPOCYP3A4 | |
| SCHEMBL324893 | 0.94 | HTR6 (1.00) | HTR6TSHRLMNAMPOCYP3A4 | |
| Dapsone SCHEMBL5055312 | 0.94 | HTR6 (1.00) | HTR6TSHRLMNAMPOCYP3A4 | |
| Dapsone SCHEMBL1219599 | 0.94 | HTR6 (1.00) | HTR6TSHRLMNAMPOCYP3A4 | |
| SCHEMBL10596934 | 0.94 | HTR6 (1.00) | HTR6TSHRLMNAMPOCYP3A4 | |
| Dapsone SCHEMBL2203636 | 0.92 | HTR6 (0.94) | HTR6TSHRLMNAMPOCYP3A4 | |
| Dapsone SCHEMBL11745790 | 0.92 | HTR6 (0.94) | HTR6TSHRLMNAMPOCYP3A4 | |
| Dapsone SCHEMBL9690514 | 0.92 | HTR6 (0.94) | HTR6TSHRLMNAMPOCYP3A4 | |
| Dapsone SCHEMBL28520980 | 0.92 | HTR6 (0.94) | HTR6TSHRLMNAMPOCYP3A4 | |
| Dapsone SCHEMBL9690505 | 0.92 | HTR6 (0.94) | HTR6TSHRLMNAMPOCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2249765-B1 | Dapsone to treat rosacea | ALLERGAN INC (US) | 2019-11-13 | — | — | EP | disclosed |
| EP-3370711-A1 | METHODS OF TREATMENT OF ACNE VULGARIS USING TOPICAL DAPSONE COMPOSITIONS | ALLERGAN, INC. (US) | 2018-09-12 | — | — | EP | disclosed |
| US-20170266138-A1 | METHODS OF TREATMENT OF ACNE VULGARIS USING TOPICAL DAPSONE COMPOSITIONS | ALMIRALL, LLC | 2017-09-21 | — | — | US | disclosed |
| WO-2017079644-A1 | METHODS OF TREATMENT OF ACNE VULGARIS USING TOPICAL DAPSONE COMPOSITIONS | ALLERGAN, INC. (US) | 2017-05-11 | — | — | WO | disclosed |
| US-20170071882-A1 | DAPSONE TO TREAT ROSACEA | ALLERGAN, INC. | 2017-03-16 | — | — | US | disclosed |
| US-9504661-B2 | Dapsone to treat rosacea | ALLERGAN, INC. (US) | 2016-11-29 | — | — | US | disclosed |
| US-20140050680-A1 | DAPSONE TO TREAT ROSACEA | ALLERGAN, INC. (US) | 2014-02-20 | — | — | US | disclosed |
| US-8586010-B2 | Dapsone to treat rosascea | ALLERGAN, INC. (US) | 2013-11-19 | — | — | US | disclosed |
| US-20130165526-A1 | TOPICAL TREATMENT WITH DAPSONE IN G6PD-DEFICIENT PATIENTS | ALLERGAN, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| EP-2364698-A2 | COMPOSITION FOR CONTROL OF AGING AND / OR EXTENSION OF LIFE, CONTAINING DAPSONE AS ACTIVE INGREDIENT | SNU R&DB Foundation (KR) | 2011-09-14 | — | — | EP | disclosed |
| US-20110152379-A1 | COMPOSITION FOR CONTROL OF AGING AND/OR EXTENSION OF LIFE, CONTAINING DAPSONE AS ACTIVE INGREDIENT | SNU R&DB FOUNDATION (KP) | 2011-06-23 | — | — | US | disclosed |
| US-20100310480-A1 | DAPSONE TO TREAT ROSASCEA | ALLERGAN, INC. | 2010-12-09 | — | — | US | disclosed |
| EP-2249765-A1 | DAPSONE TO TREAT ROSASCEA | Allergan, Inc. (US) | 2010-11-17 | — | — | EP | disclosed |
| WO-2010011111-A4 | COMPOSITION FOR CONTROL OF AGING AND / OR EXTENSION OF LIFE, CONTAINING DAPSONE AS ACTIVE INGREDIENT | 서울대학교산학협력단 (KR) | 2010-05-14 | — | — | WO | disclosed |
| WO-2010011111-A2 | COMPOSITION FOR CONTROL OF AGING AND / OR EXTENSION OF LIFE, CONTAINING DAPSONE AS ACTIVE INGREDIENT | 서울대학교산학협력단 (KR) | 2010-01-28 | — | — | WO | disclosed |
| WO-2009108147-A1 | DAPSONE TO TREAT ROSASCEA | QLT USA, INC. (US) | 2009-09-03 | — | — | WO | disclosed |
| WO-2009061298-A1 | TOPICAL TREATMENT WITH DAPSONE IN G6PD-DEFICIENT PATIENTS | QLT USA, INC. (US) | 2009-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170266138-A1 | METHODS OF TREATMENT OF ACNE VULGARIS USING TOPICAL DAPSONE COMPOSITIONS | RARG, ALAD, RARA | HTR6 4395/4885TSHR 2970/4885LMNA 2795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.